These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8274744)

  • 21. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
    Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.
    Montagna D; Yvon E; Calcaterra V; Comoli P; Locatelli F; Maccario R; Fisher A; Cavazzana-Calvo M
    Blood; 1999 May; 93(10):3550-7. PubMed ID: 10233908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL; Atasoylu AA
    Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
    Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
    Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation.
    Mavroudis DA; Jiang YZ; Hensel N; Lewalle P; Couriel D; Kreitman RJ; Pastan I; Barrett AJ
    Bone Marrow Transplant; 1996 May; 17(5):793-9. PubMed ID: 8733700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attenuation of GVHD for allo-bone marrow transplantation recipient by FasL-Fas pathway in an H-2 haplotype disparate mouse combination.
    Liu L; Zou P; Hu Z; Zhong Z; Xiao J; Guo R; Xu Z
    J Huazhong Univ Sci Technolog Med Sci; 2004; 24(4):329-33. PubMed ID: 15587391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
    Hartwig UF; Robbers M; Wickenhauser C; Huber C
    Blood; 2002 Apr; 99(8):3041-9. PubMed ID: 11929798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of marrow graft rejection without induction of graft-versus-host disease by a cytotoxic T-cell clone that recognizes recipient alloantigens.
    Kusunoki Y; Chen W; Martin PJ
    Blood; 1998 Jun; 91(11):4038-44. PubMed ID: 9596647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody.
    Cavazzana-Calvo M; Sarnacki S; Haddad E; De Coene C; Calise D; Yvon E; Cerf-Bensussan N; Fischer A
    Transplantation; 1995 Jun; 59(11):1576-82. PubMed ID: 7778173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of Alloreactive T-Cells by Anti-CD137-Saporin Immunotoxin.
    Lee SC; Seo KW; Kim HJ; Kang SW; Choi HJ; Kim A; Kwon BS; Cho HR; Kwon B
    Cell Transplant; 2015; 24(6):1167-81. PubMed ID: 24594433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice.
    Vallera DA; Taylor PA; Sprent J; Blazar BR
    Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of T cell depletion from spleen cell allografts on graft-versus-host disease and long-term immune reconstitution in H-2 haplotype-identical murine combinations.
    Tokuda N; Mayumi H; Sakumoto M; Himeno K; Tomita Y; Nomoto K
    Immunobiology; 1989 Oct; 179(4-5):328-41. PubMed ID: 2515151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific tolerance induction of allo-K(b)-skin grafts by FK506 in the CD8-depleted H-2(k) recipients required low amounts of K(b)-antigen.
    Chen BG; Liu Z; Wu Y
    Transpl Immunol; 2005 Oct; 15(1):9-16. PubMed ID: 16223668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.
    Solomon SR; Tran T; Carter CS; Donnelly S; Hensel N; Schindler J; Bahceci E; Ghetie V; Michálek J; Mavroudis D; Read EJ; Vitetta ES; Barrett AJ
    Cytotherapy; 2002; 4(5):395-406. PubMed ID: 12473206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow.
    Blazar BR; Taylor PA; Sehgal SN; Vallera DA
    Blood; 1994 Jan; 83(2):600-9. PubMed ID: 8286755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.